Date: 2013-07-30
Type of information: Collaboration agreement
Compound: ConfirmMDx™ for prostate cancer test
Company: MDX Health (Belgium) - MultiPlan (USA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On July 30, 2013, MDxHealth, a belgian molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, has announced that it has entered into agreement with MultiPlan. The agreement provides expanded access to the company\'s ConfirmMDx for Prostate Cancer test to the network\' s combined 57 million covered lives within the United States.
MultiPlan, Inc. is a provider of healthcare cost management solutions. Clients include insurers/health plans, third-party administrators, self-funded employers, HMOs and other entities that pay medical bills in the commercial healthcare, government, workers compensation and auto markets. MultiPlan contracts with 900,000 healthcare providers across the U.S. and has an estimated 57 million consumers accessing MultiPlan network products.
Financial terms:
Latest news:
